A Randomized, Double-blind, Placebo-controlled Phase Ⅰb/Ⅱ Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10506 in Chinese Adult Participants With Insomnia Disorder
Latest Information Update: 26 Apr 2024
At a glance
- Drugs HS 10506 (Primary)
- Indications Insomnia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 22 Apr 2024 Planned initiation date changed from 1 Mar 2024 to 1 May 2024.
- 02 Mar 2024 New trial record